(Updated - August 17, 2022 4:23 PM EDT)

bluebird bio's (NASDAQ: BLUE) cell-based gene therapy, Zynteglo, has been approved ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments FDA Hot List

bluebird bio (BLUE) Falls to Low, Down 18%August 18, 2022 10:38 AM bluebird bio Announces U.S. Commercial Infrastructure to Enable Patient Access to ZYNTEGLO®, the First and Only FDA-Approved Gene Therapy for People with Beta-Thalassemia Who Require Regular Red BlooAugust 17, 2022 2:32 PM bluebird bio (BLUE) Resumes Trading, Up 20%August 17, 2022 2:30 PM bluebird bio (BLUE) to Resume Trading at 2:30 p.m.August 17, 2022 2:10 PM bluebird bio (BLUE) Confirms FDA Approval of ZYNTEGLO Gene TherapyAugust 17, 2022 2:05 PM bluebird bio Announces FDA Approval of ZYNTEGLO®, the First Gene Therapy for People with Beta-Thalassemia Who Require Regular Red Blood Cell TransfusionsAugust 17, 2022 2:03 PM FDA Approves bluebird bio's (BLUE) Cell-Based Gene Therapy to Treat Adult and Pediatric Patients with Beta-thalassemia Who Require Regular Blood TransfusionsAugust 17, 2022 1:40 PM